Figure 2 is a flow chart that summarizes the design of the two arms of the Women’s Health Initiative hormone therapy trials. The estrogen plus progestin versus placebo arm inluded a 5.2-year followup phase and reported the following outcomes: mortality; breast, colorectal, lung, endometrial, and ovarian cancer; diabetes; gallbladder disease; cognitive function; fractures; coronary heart disease; stroke; thromboembolic disease (deep vein thrombosis or pulmonary embolism); and urinary incontinence. The next followup of the estrogen plus progestin versus placebo arm was the postintervention phase, and reported 8.6 years of cumulative data on the following outcomes: mortality; breast, colorectal, lung, and endometrial cancer; fractures; coronary heart disease; stroke; and thromboembolic disease (deep vein thrombosis or pulmonary embolism). The next followup of the estrogen plus progestin versus placebo arm was the extension phase, and reported 11 years of cumulative data on breast cancer. The estrogen versus placebo arm of the trial included a 6.8-year followup phase and reported the following outcomes: mortality; breast, colorectal, and lung cancer; diabetes; gallbladder disease; cognitive function; fractures; coronary heart disease; stroke; thromboembolic disease (deep vein thrombosis or pulmonary embolism); and urinary incontinence. The next followup of the estrogen versus placebo arm was the postintervention phase, with 7.8 years of followup. The next phase of the estrogen versus placebo arm was the extension phase, with 10.7 years of cumulative data, and reported the following outcomes: mortality; breast and colorectal cancer; fractures; coronary heart disease; stroke; and thormboembolic disease (deep vein thrombosis or pulmonary embolism).

Figure 2Design of the Women’s Health Initiative Hormone Therapy Trials

Abbreviations: CHD=coronary heart disease; DVT=deep vein thrombosis; E=estrogen; HT=hormone therapy; P=progestin; PE=pulmonary embolus.

From: 3, RESULTS

Cover of Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations.
Evidence Syntheses, No. 93.
Nelson HD, Walker M, Zakher B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.